The American pharmaceutical manufacturer Eli Lilly had a worse quarter than expected.
In the company's report, it reports an adjusted result per share of 1.18 dollars. This can be compared to the analysts' forecast of 1.51 dollars.
The turnover increased to 11.44 billion dollars, an increase of 20 percent compared to the same period last year. The analysts had expected a turnover of 12.18 billion dollars.
Eli Lilly announces at the same time that it is lowering its forecast for the full year 2024. The sales of Zepbound, the company's medication for weight loss, fell short of market expectations during the third quarter.
